

References

I-171

1. Thomson Micromedex DrugDex Compendium®. Ocrelizumab Ocrevus. 2017.
2. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. Ocrelizumab Ocrevus.
3. Genentech. Positive Phase III Results of Genentech's Investigational Medicine OCREVUS (Ocrelizumab) Published in New England Journal of Medicine. India Pharma News. 2015;1-4.
4. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;209-20.
5. Ocrevus (ocrelizumab) [package insert]. South San Francisco, CA. Genentech, Inc. 11/2018.
6. Hayes, Inc. Health Technology Brief. Ocrelizumab (Ocrevus; Genentech Inc.) for Primary Progressive and Relapsing-Remitting Multiple Sclerosis. Landsdale, PA: Hayes, Inc.; October 5, 2017. Accessed January 4, 2019.
7. Gelfand J, Cree B, & Hauser S. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics. 2017;14:835-841.
8. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).